In 2008, Dawood, et al. [11] reported that HER2-positivity does not affect recurrence-free survival in IBC but that hazard of death is lower in HER2-positive IBC compared to HER2-negative IBC. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.